Diluted HEPS from total operations declined to 87.5cps (-17.1% y-y). Normalised EPS from total operations declined to 94.6cps (-1.9% y-y).
Turnover from continuing operations +10.3% y-y to R22.6bn.
Expense growth of +13.6% y-y to R20.4bn, with expenses-to-sales up to 90.4% in FY23 (FY22: 87.7%).
OPM down to 10.8% in FY23 (FY22: 13.5%)
Dividend of 44cps.
Gross debt decreased to R13.0bn in FY23 (FY22: R13.3bn).
In October, the group announced the proposed disposal of its investment in Alliance Medical Group (AMG), subject to certain conditions and a shareholder vote on 8 December 2023.
International segment now only includes radiopharmaceutical products developed by LMI, as AMG has been classified as a discontinued operation.
Medical PPDs grew 20.6% y-y in FY23, while surgical PPDs grew by 10.1% y-y. This strong PPD growth translated to higher occupancies across acute hospital facilities.
